Original Article

Analysis of the efficacy and prognosis of hematopoietic stem cell transplantation for inherited bone marrow failure syndrome in children

  • ZHAO Linchao ,
  • WANG Yingjie ,
  • JING Zhaohe ,
  • MAI Yumiao ,
  • SUN Pan ,
  • QIU Simin ,
  • NIU Hongyun ,
  • CHEN Zhiwei ,
  • DONG Pengpeng ,
  • LIU Jian
Expand
  • 1. Department of Pediatrics, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, China
    2. Department of Pediatrics, Henan Children’s Hospital, Zhengzhou 450052, Henan, China

Received date: 2024-07-08

  Accepted date: 2024-12-26

  Online published: 2025-06-27

Abstract

Objective To observe the efficacy and prognosis of hematopoietic stem cell transplantation (HSCT) in the treatment of inherited bone marrow failure syndromes (IBMFs) in children. Methods The clinical data of children with IBMFs who underwent HSCT in the First Affiliated Hospital of Zhengzhou University from January 2019 to November 2023 were collected, and their clinical characteristics, transplantation preconditioning regimen, hematopoietic reconstruction, and prognosis were analyzed. Results A total of 18 children with IBMFs were enrolled, including 7 cases of Fanconi anemia (FA), 5 cases of dyskeratosis congenita (DKC), 3 cases of Diamond-Blackfan anemia (DBA), 2 cases of congenital amegakaryocytic thrombocytopenia (CAMT) and 1 case of severe congenital neutropenia (SCN). There were 10 boys and 8 girls, with a median age of 8.2 (1.2-14.0) years. The median time of neutrophil engraftment was 11 (9-21) days, and the median time of platelet engraftment was 13 (10-30) days. During the median follow-up of 10.6 (1.0-62.9) months, the bone marrow of 18 patients was completely chimeric. A total of 8 patients developed acute graft-versus-host disease (GVHD), including 2 cases of grade Ⅳ, 2 cases of grade Ⅲ, 1 case of grade Ⅱ, and 3 cases of grade Ⅰ. Two children suffered from mild chronic GVHD. Fifteen patients survived and 3 died. Two children with FA developed transplant-related thrombotic microangiopathy, and they were treated with plasma exchange or defibrotide with poor results, and all died of multiple organ failure. One CAMT patient developed a severe pulmonary infection 28 days after transplantation, and his condition progressed rapidly, ultimately leading to respiratory failure. Conclusions HSCT is an effective method for the treatment of IBMFs in children. According to the different diseases of children with IBMFS, the appropriate preconditioning regimen can be selected to obtain a better curative effect and prognosis.

Cite this article

ZHAO Linchao , WANG Yingjie , JING Zhaohe , MAI Yumiao , SUN Pan , QIU Simin , NIU Hongyun , CHEN Zhiwei , DONG Pengpeng , LIU Jian . Analysis of the efficacy and prognosis of hematopoietic stem cell transplantation for inherited bone marrow failure syndrome in children[J]. Journal of Clinical Pediatrics, 2025 , 43(7) : 505 -510 . DOI: 10.12372/jcp.2025.24e0699

References

[1] Lu Y, Xiong M, Sun RJ, et al. Hematopoietic stem cell transplantation for inherited bone marrow failure syndromes: alternative donor and disease-specific conditioning regimen with unmanipulated grafts[J]. Hematology, 2021, 26(1): 134-143.
[2] Giudice V, Gurnari C, Pagliuca S, et al. Editorial: endocrinological sequelae of hematopoietic stem cell transplantation[J]. Front Endocrinol (Lausanne), 2023, 14: 1151213.
[3] Pierri F, Faraci M, Giardino S, et al. Hematopoietic stem cell transplantation for classical inherited bone marrow failure syndromes: an update[J]. Expert Rev Hematol, 2021, 14(10): 911-925.
[4] 孙若楠, 李泊涵, 郑德菲, 等. 儿童异基因造血干细胞移植100天后闭塞性细支气管炎综合征临床特点及危险因素分析[J]. 临床儿科杂志, 2024, 42(2): 139-145.
  Sun RN, Li BH, Zheng DF, et al. Factors related to bronchiolitis obliterans syndrome in pediatric patients survived longer than 100 days after hematopoietic stem cell transplantation[J]. Linchuang Erke Zazhi, 2024, 42(2): 139-145.
[5] 罗明静, 余嘉明, 王晓东, 等. 424例地中海贫血患儿异基因造血干细胞移植后继发侵袭性真菌病临床分析[J]. 临床儿科杂志, 2025, 43(1): 21-28.
  Luo MJ, Yu JM, Wang XD, et al. Clinical analysis of invasive fungal disease secondary to allogeneic hematopoietic stem cell transplantation in 424 children with thalassemia[J]. Linchuang Erke Zazhi, 2025, 43(1): 21-28.
[6] Elghetany MT, Punia JN, Marcogliese AN. Inherited bone marrow failure syndromes: biology and diagnostic clues[J]. Clin Lab Med, 2021, 41(3): 417-431.
[7] Peffault de Latour R, Peters C, Gibson B, et al. Recom-mendations on hematopoietic stem cell transplantation for inherited bone marrow failure syndromes[J]. Bone Marrow Transplant, 2015, 50(9): 1168-1172.
[8] Li Q, Luo C, Luo C, et al. Disease-specific hematopoietic stem cell transplantation in children with inherited bone marrow failure syndromes[J]. Ann Hematol, 2017, 96(8): 1389-1397.
[9] Dignan FL, Clark A, Amrolia P, et al. Diagnosis and management of acute graft-versus-host disease[J]. Br J Haematol, 2012, 158(1): 30-45.
[10] Dignan FL, Amrolia P, Clark A, et al. Diagnosis and management of chronic graft-versus-host disease[J]. Br J Haematol, 2012, 158(1): 46-61.
[11] Balassa K, Danby R, Rocha V. Haematopoietic stem cell transplants: principles and indications[J]. Br J Hosp Med (Lond), 2019, 80(1): 33-39.
[12] Chattopadhyay S, Lionel S, Selvarajan S, et al. Fludarabine-based low-intensity conditioning for Fanconi anemia is associated with good outcomes in aplastic anemia but not in MDS - a single-center experience[J]. Mediterr J Hematol Infect Dis, 2023, 15(1): e2023039.
[13] Bhoopalan SV, Wlodarski M, Reiss U, et al. Reduced-intensity conditioning-based hematopoietic cell transplantation for dyskeratosis congenita: Single-center experience and literature review[J]. Pediatr Blood Cancer, 2021, 68(10): e29177.
[14] Giardino S, Pierri F, Faraci M. How to optimize outcome of patients undergoing HLA-matched related haematopoietic stem cell transplantation in acquired and inherited bone marrow failure syndromes[J]. Br J Haematol, 2023, 203(2): 158-160.
[15] Giri N, Ravichandran S, Wang Y, et al. Prognostic significance of pulmonary function tests in dyskeratosis congenita, a telomere biology disorder[J]. ERJ Open Res, 2019, 5(4): 0209-2019.
[16] Bhoopalan SV, Suryaprakash S, Sharma A, et al. Hematopoietic cell transplantation and gene therapy for Diamond-Blackfan anemia: state of the art and science[J]. Front Oncol, 2023, 13: 1236038.
[17] Liu Y, Karlsson S. Perspectives of current understanding and therapeutics of Diamond-Blackfan anemia[J]. Leukemia, 2024, 38(1): 1-9.
[18] Bartels M, Bierings M. How I manage children with Diamond-Blackfan anaemia[J]. Br J Haematol, 2019, 184(2): 123-133.
[19] Alada? E, Kelkitli E, G?ker H. Acute graft-versus-host disease: a brief review[J]. Turk J Haematol, 2020, 37(1): 1-4.
Outlines

/